Company / Capital Expenditures
Edwards Lifesciences Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$260.2M
FY2025
5-year range
$244.6M / $325.8M
FY2021-FY2025
Trend
+3.1%
vs FY2024
Sector context
#37 of 151
Health Care
What the data says
Edwards Lifesciences's capital expenditures of $260M is higher than 75% of companies in the Health Care sector (FY2025). Capital Expenditures has fluctuated over the past 10 years, ranging from $168M in FY2017 to $407M in FY2020.
Based on SEC 10-K filings.
$260M in FY2025 with a 5-year CAGR of -8.6%. Top quartile in the Health Care sector.
Declined from $326M to $260M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +2.1%
- 5-Year CAGR
- -8.6%
- 10-Year CAGR
- -
Sector benchmark
-4.2% below sector average
Key checks
Key Insights
- 5-year CAGR of -8.6%, indicating a declining trend.
- In FY2025, capital expenditures increased 3.1% year-over-year.
- Ranks #37 out of 151 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score 3.16 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $260.2M | +3.1% |
| FY2024 | $252.4M | -22.5% |
| FY2023 | $325.8M | +33.2% |
| FY2022 | $244.6M | -24.9% |
| FY2021 | $325.8M | -20.0% |
| FY2020 | $407.0M | +60.0% |
| FY2019 | $254.4M | +6.6% |
| FY2018 | $238.7M | +42.0% |
| FY2017 | $168.1M | -4.5% |
| FY2016 | $176.1M | +71.5% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026